Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) in Patients With Sarcoma or Gastrointestinal Tract Cancer (PHANTOM Trial)

NCT06298916 is registered in ClinicalTrials.gov with Lantheus Medical Imaging as lead sponsor.

NCT NCT06298916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06298916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) in Patients With Sarcoma or Gastrointestinal Tract Cancer (PHANTOM Trial)
Lead sponsor
Lantheus Medical Imaging
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 31, 2025
Completion date
April 30, 2026
Enrollment
26 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, esophageal cancer, gastric cancer, metastatic sarcoma, pancreatic cancer, sarcoma